Markets
Luke Kawa

In nearly 30 years, the S&P 500 hasn’t had a day like this


The S&P 500 had its worst session since the end of April, falling 0.9% as the Magnificent Seven proved a misnomer — at least for today.

A soft US CPI inflation print catalyzed a violent rotation out of what had been working this year into what has been lagging, with interest-rate sensitive sectors also performing well.

This was a day for the record books.

Breadth within the S&P 500 was exceptional: nearly 400 stocks rose. The S&P 500 has never suffered a loss this large with that many stocks moving higher versus lower in data going back to October 1996.

The Russell 2000 Index of small-cap stocks had its best day since November, up 3.5%, while the Bloomberg Magnificent Seven Index of tech titans fell 4.2%, its worst day since October 2022. The performance gap between the two was the largest going back to at least April 2015.

Lower-than-expected inflation fueled a rally in bonds, helping make real estate the best-performing S&P sector ETF. Its 2.7% gain was the biggest for the sector all year. Utilities, another rate-sensitive pocket of the market, gained 1.8%.

The SPDR S&P Homebuilders ETF did even better, up a whopping 5.9% in its best day since October 2022.

The tech sector ETF was trounced, down 2.5%, with communication services and consumer discretionary also off more than 1%. Nvidia, Tesla, Microsoft, Apple, Google, Amazon, and Meta all fell more than 2%.

There were also some earnings stories that weighed on the market as well. In particular, Delta fell 4% after reporting quarterly results that disappointed and stirred fears of industry-wide overcapacity even amid high travel.

More Markets

See all Markets
markets

Broadcom soars on Google’s plans for up to $185 billion in capex this year

Google’s capex guidance is Broadcom’s earnings guidance.

The hyperscaler and search giant said its 2026 capex budget would be between $175 billion and $185 billion, 55% higher than Wall Street had anticipated.

Accordingly, shares of the custom chip specialist are soaring in after-hours trading.

Broadcom has enjoyed a halo effect from Google’s capex plans and the success of its Gemini 3 model (trained on TPUs the two companies codesigned) over the past year.

But the custom chip designer had tumbled after its most recent earnings report, with some analysts attributing the decline to the dearth of new customer announcements. But who needs new customers when your current ones are opening their wallets this much?!?

Accordingly, shares of the custom chip specialist are soaring in after-hours trading.

Broadcom has enjoyed a halo effect from Google’s capex plans and the success of its Gemini 3 model (trained on TPUs the two companies codesigned) over the past year.

But the custom chip designer had tumbled after its most recent earnings report, with some analysts attributing the decline to the dearth of new customer announcements. But who needs new customers when your current ones are opening their wallets this much?!?

(J. Edward Moreno/Sherwood News)

Novo and Lilly agree prices are falling — and disagree on what comes next

Novo Nordisk and Eli Lilly are cutting prices to reach more patients — with sharply different expectations about what that means for sales.

markets

Ozempic is no longer the most searched for GLP-1 in the US

Ozempic, the popular diabetes drug made by Novo Nordisk, used to be shorthand for an entire class of diabetes and weight-loss medications. Not anymore.

According to Google Trends data, as of January, more people in the US are searching for Eli Lilly’s weight-loss shot, Zepbound, than Ozempic. At the same time, interest in the word “Ozempic” now sits roughly on par with searches for “peptides,” a catchall term for a booming, loosely regulated category of experimental supplements.

The numbers hint at a cultural shift: Ozempic is no longer the only word people reach for when they think about weight-loss drugs. The market — and the vocabulary around it — is fragmenting.

This shift also reflected in sales numbers. For several quarters now, Lillys diabetes and weight-loss drugs have outsold Novos, and that gap is expected to widen this year.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.